Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-20
2005-09-20
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S450000
Reexamination Certificate
active
06946456
ABSTRACT:
The present invention concerns methods for treating cell proliferative diseases, tumors associated with viral infections, and certain viral infections. The disclosed methods use compounds which inhibit heat shock protein 90 proteins. Such methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction.
REFERENCES:
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 5387584 (1995-02-01), Schnur
patent: 5650430 (1997-07-01), Sugimura et al.
patent: 5932566 (1999-08-01), Schnur et al.
patent: 5968921 (1999-10-01), Gold
patent: 6210974 (2001-04-01), Gold
patent: 6239168 (2001-05-01), Ino et al.
patent: 6335157 (2002-01-01), Gonzalez et al.
patent: 6413975 (2002-07-01), Chasin et al.
patent: 6440982 (2002-08-01), Maw et al.
patent: WO 00/61578 (2000-10-01), None
Chiosis et al. A small molecule designed to bind . . . Chemistry & Biology. Mar. 7, 2001, vol. 8, No. 3, pp. 289-299.
Hosokawa et al. Hydroxymycotrienins A and B, New Ansamycin Group Antibiotics. The Journal Of Antibiotics. May 1996, vol. 49, No. 5, pp. 425-431.
Srethapakdi et al. Herbimycin A reveals a role for Rb in mitosis. Proceedings of the American Association for Cancer Research. Mar. 1999, vol. 40, p. 11, Abstract #72.
Chavany, et al., “p185tabB2Binds to GRP94 in Vivo”, Journal of Biological Chemistry, vol. 271, No. 9 Mar. 1, 1996, pps. 4974-4977.
Neckers, “Effects of Geldanamycin and Other Naturally Occuring Small Molecule Antagonists of Heat Shock Protein 90 on HER2 Protein Expression”, Breast Disease 11 (2000) 49-59. pps. 49-59.
Schnur, et al. “erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure—Activity Relationships”, J. Med. Chem. 1995, 38, 3813-3820.
Munster, et al. Inhibition of Heat Shock Protein 90 Function by Ansamycins Causes the Morphological and Functional Differentiation of Breast Cancer Cells, Cancer Research. Apr. 1, 2001, vol. 61, pp. 2945-2952, especially the Abstract, p. 2950, col. 2, first full paragraph, p. 2951, col. 1, third full paragraph.
Neckers, “Effects of Geldanamycin and Other Naturally Occuring Small Molecule Antagonists of Heat Shock Protein 90 on HER2 Protein Expression”, Breast Disease 11 (2000) 49-59. pps. 49-59.
Schnur, et al. “erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure—Activity Relationships”, J. Med. Chem. 1995, 38, 3813-3820.
Chavany, et al., “p185subB2Binds to GRP94 in Vivo”, Journal of Biological Chemistry, vol. 271, No. 9 Mar. 1, 1996, pps. 4974-4977.
Schulte et al. “The benzoquinone ansarnycin 17-allylamino-17-demethoxyge Idanamycin binds to HSP90 and shares important biologic activities with geldanamycin”, Canc er Chemotherapy and Pharmacology, 1998, vol. 42, pp 273-279.
Hurst, et al., “HSP90 inhibitors block the mitotic checkpoint and are synergistically toxic with spindle poisons”, Clinical Cancer Res., Nov. 1999, vol. 8, p. 3788s, #293.
Kherfellah, d., et al., “Effect of the combination of topoisomerase I and topoisomerase II inhibitors on rat glioblastoma cells and drug-resistant varian ts”, Pharmacol. Experimental Therapeutics, Mar. 1999, vol. 40, p. 109, #724, Proceedings of the American Association for Cancer Research.
Stebbins, C.E., et al., “Crystal structure of the HSP90-Geldanamycin complex: targeting of a protein chaperone by an antitumor agent”, Cell, Apr. 1997, vol. 89, pp. 239-240 and 246-248.
Rosenhagen, M.C. et al. “Synergistic inhibition of the Glucocorticoid receptor by radicicol and benzoquinone ansamycins”, Biol. Chem., Mar. 2001, vol. 382, pp. 499-504.
Kato, et al. “Synthesis of Compounds Related to Antitumor Agents IV on the Reaction of Aromatic Carboxylates with 2, 4 Diamino-5-hydroxy-6-methylpyrimidine”, Chem. Pharm. Bull. 1976, vol. 24, No. 10, pp 2461-2469. See Table 2.
Black et al., “Reaction of Ninhydrin With Activated anilines: Formation of Indole Derivatives”, letrahedron. 1994, vol. 50, No. 37, pp 10983-10994. See Compound 17.
Rosen Neal
Srethapakdi Mary
Oppedahl & Larson LLP
Russel Jeffrey Edwin
Sloan-Kettering Institute for Cancer Research
LandOfFree
Methods for treating cell proliferative disorders and viral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cell proliferative disorders and viral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cell proliferative disorders and viral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3405690